Clavis Pharma, Clovis Oncology and Ventana Medical Systems have entered into a collaboration agreement to develop a companion diagnostic to CP-4126, Clavis’s lead cancer drug candidate.

The companion diagnostic will be developed to identify pancreatic cancer patients with low-level tumour expression of the human equilibrative nucleoside transporter 1 protein who may be benefited from the company’s novel drug candidate.

CP-4126 has been licensed to Clovis in the Americas and Europe while Clavis retains rights in other regions and an option to co-promote CP-4126 in Europe.